Is Everest Organics overvalued or undervalued?

As of 14 November 2025, Everest Organics has moved from an expensive valuation grade to fair. The company is currently fairly valued, with a PE ratio of 62.63, an EV to EBITDA ratio of 27.20, and a PEG ratio of 0.31. These ratios suggest that while the stock is priced higher than some peers, its growth potential is being recognized, especially given the low PEG ratio indicating potential undervaluation relative to growth.
In comparison to its peers, Everest Organics has a higher PE ratio than Sun Pharma (36.49) and a lower PEG ratio than Divi's Lab (1.97), which is categorized as very expensive. Notably, the company has demonstrated strong performance with a year-to-date return of 41.84%, significantly outpacing the Sensex return of 8.22% during the same period, reinforcing the notion that the stock may be fairly valued given its growth trajectory.